Patricia de Cremoux, Mathieu Dalvai, Olivia N'Doye, Fatima Moutahir, Gaëlle Rolland, Olfa Chouchane-Mlik, Franck Assayag, Jacqueline Lehmann-Che, Laurence Kraus-Berthie, André Nicolas, Brian Paul Lockhart, Elisabetta Marangoni, Hugues de Thé, Stéphane Depil, Kerstin Bystricky, Didier Decaudin
Several publications have suggested that histone deacetylase inhibitors (HDACis) could reverse the repression of estrogen receptor alpha (ERα) in triple-negative breast cancer (TNBC) cell lines, leading to the induction of a functional protein. Using different HDACis, vorinostat, panobinostat, and abexinostat, we therefore investigated this hypothesis in various human TNBC cell lines and patient-derived xenografts (PDXs). We used three human TNBC cell lines and three PDXs. We analyzed the in vitro toxicity of the compounds, their effects on the hormone receptors and hormone-related genes and protein expression both in vitro and in vivo models...
January 2015: Breast Cancer Research and Treatment